Milestone poultry vaccine submission

Eco Animal Health reports that it has submitted a key Market Authorisation Application (MAA) to the European Medicines Agency (EMA), with supporting documentation, for its ECOVAXXIN^®MS, Mycoplasma synoviae, vaccine. This represents an important step towards commercialisation for ECOVAXXIN^®MS, one of nine major new vaccines under development. This is a process which we expect to be replicated and as CEO David Hallas notes, this “represents a pivotal moment for ECO”. Significantly, the Group continues to submit technical data to the US Department of Agriculture (USDA) for both ECOVAXXIN^® Mycoplasma synoviae and ECOVAXXIN^® Mycoplasma gallisepticum (MG), and expects to gain marketing approval in the US, subject to dossier review, at about the same time as in Europe.